Human epidermal growth factor receptor 2 (HER2)-positive BC accounts for approximately 15–20% of BCs and is associated with an aggressive phenotype, high recurrence rates and inferior survival outcomes, if left untreated [3]. Here, ERBB2 is linked to breast cancer.